HomeAI · summaries
Storia in 3 fonti
Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
Hengrui/Kailera's GLP-1 pill HRS-7535 met obesity & diabetes China trial endpoints but showed high nausea & vomiting, raising concerns vs Lilly & Novo pills.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Kailera says obesity pill succeeds in late-stage trial in China
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
- ·
endpoints.news
Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
Hengrui/Kailera's GLP-1 pill HRS-7535 met obesity & diabetes China trial endpoints but showed high nausea & vomiting, raising concerns vs Lilly & Novo pills.
